PMID- 29088891
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 43
DP  - 2017 Sep 26
TI  - Cost-utility of stereotactic radiation therapy versus proton beam therapy for 
      inoperable advanced hepatocellular carcinoma.
PG  - 75568-75576
LID - 10.18632/oncotarget.17369 [doi]
AB  - The cost-utility of proton beam therapy was compared to stereotactic body 
      radiation therapy for inoperable advanced hepatocellular carcinoma. A Markov 
      decision-analytic model was performed following time to progression and survival 
      using phase II trial data. Patients transitioned between three health states. 
      Clinical outcomes were estimated for quality of life using utility estimates in 
      the published literature and measured as incremental cost-effectiveness ratios 
      (ICERs) and net monetary benefits (NMBs). Real direct medical costs were 
      extracted from the Bureau of National Health Insurance database. One-way and 
      probabilistic sensitivity analyses assessed the impact of specific variables on 
      the model. In the base-case scenario, the modeled median survival was 16 months 
      for proton beam therapy and 10 months for SBRT. Proton beam therapy resulted in 
      an additional 2.61 quality-adjusted life years (QALYs) at an incremental cost of 
      NT$ 557,907 compared to SBRT. The ICER was NT$ 213,354 per QALY gained. The 
      probabilistic sensitivity analysis predicted a 97 % chance of proton beam therapy 
      being cost-effective at the willingness to pay NT$2,157,024 per QALY gained. 
      Thus, proton beam therapy is a cost-effective therapy for inoperable advanced 
      hepatocellular carcinoma at the willingness-to-pay threshold of Taiwan.
FAU - Leung, Henry W C
AU  - Leung HWC
AD  - Department of Radiation Oncology, An Nan Hospital, China Medical University, 
      Tainan, Taiwan.
AD  - Department of Nursing, Min-Hwei College of Health Care Management, Tainan, 
      Taiwan.
FAU - Chan, Agnes L F
AU  - Chan ALF
AD  - Department of Nursing, Min-Hwei College of Health Care Management, Tainan, 
      Taiwan.
AD  - Department of Pharmacy, An Nan Hospital, China Medical University, Tainan, 
      Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20170421
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC5650446
OTO - NOTNLM
OT  - ICER
OT  - NMB
OT  - SBRT
OT  - WTP
OT  - proton beam
COIS- CONFLICTS OF INTEREST We did not have any conflict of interest.
EDAT- 2017/11/02 06:00
MHDA- 2017/11/02 06:01
PMCR- 2017/09/26
CRDT- 2017/11/02 06:00
PHST- 2016/10/24 00:00 [received]
PHST- 2017/04/11 00:00 [accepted]
PHST- 2017/11/02 06:00 [entrez]
PHST- 2017/11/02 06:00 [pubmed]
PHST- 2017/11/02 06:01 [medline]
PHST- 2017/09/26 00:00 [pmc-release]
AID - 17369 [pii]
AID - 10.18632/oncotarget.17369 [doi]
PST - epublish
SO  - Oncotarget. 2017 Apr 21;8(43):75568-75576. doi: 10.18632/oncotarget.17369. 
      eCollection 2017 Sep 26.